Christina Michaelidi assumes the position of Medical Director of Pfizer Hellas as of July 3rd, 2026, succeeding Mr. Damianos Menegas. With more than 10 years of experience in Medical Affairs, Ms. Michaelidi has a strong scientific and research background, which will ensure the alignment of Pfizer’s scientific strategy with the needs of Healthcare Professionals, the healthcare system, and patients in Greece, while at the same time strengthening the company’s presence in the field of Oncology.
Ms. Michaelidi will be responsible for the entire portfolio of innovative medicines and vaccines of Pfizer Hellas, as well as the scientific support of clinical studies conducted in Greece, both by Pfizer’s local and global organization, in collaboration with public and private hospitals and university institutions for therapeutic categories such as cardiovascular diseases, oncology, rare diseases, and vaccines.
With many years of academic specialization in solid tumors and hematologic malignancies, Ms. Michaelidi joined Pfizer in 2017 as Medical Advisor in the Oncology – Hematology department, while during her career at Pfizer she also undertook roles in Pfizer’s global Medical and Research Oncology organization. From 2024 until today, she served as head of the Oncology medical department, with responsibility for Greece, Cyprus, and Malta, while she was also a member of the broader leadership team of the Medical department.
Ms. Michaelidi holds a doctoral degree (PhD) from the Medical School of the University of Athens and a postdoctoral degree (Post doctoral) in Molecular Oncology from the Medical School of Johns Hopkins University in the USA. At the same time, she holds a postgraduate degree (MSc) in Oncology from the Medical School of Athens and is a graduate of the School (BSc) of Positive Sciences of the National and Kapodistrian University of Athens. Her research work includes a significant number of publications in international scientific journals and in fields such as biomarkers, cancer epigenetics, and translational research.
Ms. Christina Michaelidi stated: “It is a great honor to assume the role of Medical Director of Pfizer Hellas. Together with the medical team of Pfizer Hellas, we will continue to invest in scientific knowledge and in strengthening the leading position of our company. Our main concern is the equal access of patients to new therapies, with the aim that global innovation translates into meaningful benefit for all patients in our country.”
On his part, Mr. Vasilis Tzinieris, Chairman & CEO of Pfizer Hellas stated: “Christina’s deep scientific training and experience substantially strengthen our company’s strategy, allowing us to accelerate innovation and create even greater value for patients, healthcare professionals, and our country’s healthcare system. At the same time, I would like to express my warm thanks to Damianos Menegas for his significant and long-standing contribution to the implementation of Pfizer Hellas’ strategy. Under his leadership, the Medical Department of Pfizer Hellas evolved into a modern and dynamic organization, with a strong scientific footprint in Greece, which we are certain Christina will further develop.”